Does Rallies show 13F holders for MBRX?

Yes. Rallies tracks hedge fund and 13F ownership data for MBRX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is MBRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MBRX. It does not provide personalized investment advice.

MBRX (Moleculin Biotech, Inc.) Stock Analysis - Hedge Fund Holdings

Moleculin Biotech, Inc. (MBRX) is a publicly traded Healthcare sector company. As of May 21, 2026, MBRX trades at $2.47 with a market cap of $11.15M and a P/E ratio of -0.08. MBRX moved +0.00% today. Year to date, MBRX is -40.00%; over the trailing twelve months it is -90.45%. Its 52-week range spans $1.79 to $91.25. Analyst consensus is strong buy with an average price target of $21.00. Rallies surfaces MBRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns MBRX stock?

Hedge funds tracked by Rallies that own MBRX include Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Moleculin Biotech, Inc..

MBRX Key Metrics

Key financial metrics for MBRX
Metric	Value
Price	$2.47
Market Cap	$11.15M
P/E Ratio	-0.08
EPS	$-28.42
Dividend Yield	0.00%
52-Week High	$91.25
52-Week Low	$1.79
Volume	218
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-33.56M
Gross Margin	0.00%

Top Hedge Funds Holding MBRX

Renaissance Technologies holds 11.50K shares of MBRX, changed +4.55% as of Dec 31, 2024.

Latest MBRX News

Moleculin Reports No Cardiotoxicity in 90-Patient Annamycin AML Safety Review — May 12, 2026
Moleculin Biotech Secures Hong Kong Patent for Annamycin Through June 2040 — May 8, 2026
Moleculin to Present Annamycin Cardiac Safety Data at 2026 ASCO Poster Session — Apr 21, 2026
Moleculin Highlights Annamycin’s Non-Cardiotoxic Profile to Support Phase 3 AML Trial — Apr 7, 2026
FDA Eases Cell Therapy Rules as Market Forecast Hits $14B by 2035 — Mar 27, 2026

Recent MBRX Insider Trades

Foster Jonathan P. bought 270.27K (~$100.00K) on Jun 23, 2025.
KLEMP WALTER V bought 675.67K (~$250.00K) on Jun 23, 2025.
Foster Jonathan P. bought 28.99K (~$20.00K) on Dec 26, 2023.

MBRX Analyst Consensus

3 analysts cover MBRX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $21.00.

Common questions about MBRX

Who owns MBRX stock?: Hedge funds tracked by Rallies that own MBRX include Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Moleculin Biotech, Inc..
Does Rallies show 13F holders for MBRX?: Yes. Rallies tracks hedge fund and 13F ownership data for MBRX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MBRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MBRX. It does not provide personalized investment advice.